BlackRock Income and Growth Investment Trust Plc - Portfolio Update
The information contained in this release was correct as at
https://www.londonstockexchange.com/exchange/news/market-news/market-news-home.html .
All information is at
Performance at month end with net income reinvested
Since
One Three One Three Five
1 April
Month Months Year Years Years
2012
Sterling
Share price -4.3% 2.7% 16.7% 28.1% 55.9% 178.7%
Net asset value -9.3% -1.1% 12.2% 29.9% 50.4% 173.7%
FTSE All-Share Total Return -6.7% 2.4% 21.5% 45.6% 69.3% 199.0%
Source: BlackRock
BlackRock took over the investment management of the Company with effect from
At month end
Sterling:
Net asset value - capital only: 240.22p Net asset value - cum income*: 243.20p Share price: 221.00p Total assets (including income): £51.4m Discount to cum-income NAV: 9.1% Gearing: 4.2% Net yield**: 3.5% Ordinary shares in issue***: 18,654,568 Gearing range (as a % of net assets): 0-20% Ongoing charges****: 1.15% * Includes net revenue of2.98 pence per share ** The Company's yield based on dividends announced in the last 12 months as at the date of the release of this announcement is 3.3% and includes the 2025 final dividend of 5.00p per share declared on28 January 2026 with pay date20 March 2026 and the Interim Dividend of 2.70p per share declared on19 June 2025 with pay date02 September 2025 . *** excludes 10,081,532 shares held in treasury. **** The Company's ongoing charges are calculated as a percentage of average daily net assets and using management fee and all other operating expenses excluding finance costs, direct transaction costs, custody transaction charges, VAT recovered, taxation and certain non-recurring items for the year ended31 October 2025 . In addition, the Company's Manager has also agreed to cap ongoing charges by rebating a portion of the management fee to the extent that the Company's ongoing charges exceed 1.15% of average net assets.
Sector Analysis Total assets (%) Banks 12.9 Pharmaceuticals & Biotechnology 10.8Oil & Gas Producers 8.9 Support Services 5.1Household Goods & Home Construction 5.0 General Retailers 5.0 Mining 4.6 Aerospace & Defence 4.4 Tobacco 4.2 Electronic &Electrical Equipment 3.4 Software & Computer Services 3.1Nonlife Insurance 2.9 General Industrials 2.9 Electricity 2.6 Financial Services 2.6 Life Insurance 2.6Industrial Engineering 2.4 Real Estate Investment Trusts 2.4 Food & Drug Retailers 2.4 Personal Goods 2.2 Food Producers 1.6 Net Current Assets 8.0 ----- Total 100.0 ===== Percentage Country AnalysisUnited Kingdom 88.0United States 4.0 Net Current Assets 8.0 ----- 100.0 ===== Fund % Top 10 Holdings AstraZeneca 8.8 Shell 6.0 HSBC 4.3 British American Tobacco 4.2 Lloyds Banking Group 4.1 Standard Chartered 3.9 Reckitt Benckiser Group 3.9 Rolls-Royce Holdings 3.2 RELX 3.1BP Group 2.9
Commenting on the markets, representing the Investment Manager noted:
Market summary:
Global equity markets came under pressure in March, driven primarily by an energy shock rather than a deterioration in corporate fundamentals. Escalating conflict in the
The macro backdrop grew more challenging as central banks struck a firmer tone, and rate
-
cut expectations were pushed out. Financial conditions tightened, the
In the
Source: https://www.bankofengland.co.uk/monetary-policy-summary-and-minutes/2026/march-2026
Stock comments:
3i Group
detracted from performance as the shares fell sharply at the end of the quarter due to a disappointing Capital Markets update.
Reckitt Benckiser detracted as the shares gave back earlier gains, having benefited at the start of the year from a shift by investors towards simpler, defensive businesses amid broader market uncertainty. Sentiment weakened following a cautious company update, where a modest earnings downgrade driven by a slightly higher tax assumption overshadowed otherwise stable underlying operations. This, combined with ongoing investor caution around the pace of volume recovery in Hygiene and Nutrition, weighed on the shares during the month, despite the company's defensive characteristics remaining intact.
Weir Group also detracted from relative returns during the month, as the shares pulled back following a strong run earlier in the year. Sentiment weakened on concerns around the timing of mining capital expenditure and potential delays to customer investment decisions, particularly in a more uncertain macro and geopolitical environment. While underlying demand drivers linked to energy transition and mine efficiency remain intact, near - term caution from investors weighed on the share price over the period.
An underweight position in
Unilever
contributed as the shares lagged the market during the month. Investor caution around consumer demand persisted, particularly in the context of higher prices and pressure on household budgets. Sentiment was further weighed down late in March following the announcement of the proposed combination of Unilever's
Rentokil
contributed to relative performance as the shares proved resilient, supported by steady trading and continued confidence in margin recovery as integration benefits from recent acquisitions feed through. This was helped by the release of full-year results early in the month, which highlighted solid cash generation and gradual improvement in
Changes:
Given the price volatility over the month caused by both idiosyncratic and geopolitical factors, we made changes to the fund taking advantage of the price dislocation, focusing on where we have greatest conviction while recognising where our theses had changed and, as per our sell discipline, necessitated sales.
We added to our position in
British American Tobacco
following recent share price weakness and after a company meeting. The holding enhances portfolio yield and capital growth potential, underpinned by a stock
-
specific investment case that is relatively uncorrelated to the broader economic cycle. We also added to
3i Group
following recent weakness, reflecting increased confidence in the cost profile and execution of Action's US expansion plans, while pricing actions and recent competitor exits support an improving outlook for
We exited
ICG
given the growing headwinds facing private credit, which are likely to be exacerbated by the conflict with
We made two sales for stock specific reasons selling Melrose and Tate & Lyle. We sold Melrose after a weak set of results, with underlying cash generation materially weaker than expected once one-off items are adjusted for, raising concerns around the quality of future cash flows. Finally, we exited Tate & Lyle as execution continues to disappoint following another unexpected cut to 2027 guidance; against an uncertain backdrop and the risk of higher inflation, we expect earnings to remain under pressure.
Outlook:
The immediate outlook for the global economy, particularly for 2026, will largely be shaped by the duration of the war in
In the
Notwithstanding the uncertainty in the
Cash-generative businesses with enduring competitive advantages continue to be a priority, and we are confident they are best positioned to deliver long-term returns. While volatility is likely to persist, the opportunities it presents are encouraging - both in resilient growth stories and compelling turnaround cases.
Release